Document:

<PAGE>   1

                                                                   EXHIBIT 10.2

                   AMENDED AND RESTATED PATENT AND TECHNOLOGY
                              ASSIGNMENT AGREEMENT

        THE PATENT AND TECHNOLOGY ASSIGNMENT AGREEMENT, dated as of April 3,
1992, as amended by that certain letter agreement dated November 16, 1994, and
amended and restated as effective this 16th day of June, 2000 (the "RESTATEMENT
EFFECTIVE DATE"), is made by and between Sunrise Technologies International,
Inc., f/k/a Laser Biotech, Inc., a Delaware corporation, having its principal
place of business at 3400 West Warren Avenue, Fremont, California 94538
(hereinafter, "SUNRISE") and Bruce J. Sand, M.D., F.A.C.S. of 638 Lindero Canyon
Road, Suite 507, Oak Park, California 91301 (hereinafter, "DR. SAND").

                              W I T N E S S E T H :

WHEREAS, Sunrise and Dr. Sand are parties to a Patent and Technology Assignment
Agreement dated as of April 3, 1992, as amended by that certain letter agreement
dated November 16, 1994 (and together with all other agreements whether oral or
written between the parties existing prior to the date hereof, the "ORIGINAL
ASSIGNMENT AGREEMENT");

WHEREAS, the parties hereto wish to amend and restate the Original Assignment
Agreement in the form of this Amended and Restated Patent and Technology
Assignment Agreement (the "AMENDED AND RESTATED PATENT AND TECHNOLOGY ASSIGNMENT
AGREEMENT");

WHEREAS, this Amended and Restated Patent and Technology Assignment Agreement is
given in amendment to, restatement of and substitution for the Original
Assignment Agreement;

WHEREAS, the parties to this Amended and Restated Patent and Technology
Assignment Agreement shall simultaneously enter into that certain Royalty
Acceleration Agreement dated June 16, 2000 (the "ROYALTY ACCELERATION
AGREEMENT") whereby Sunrise and Dr. Sand agree to amend and alter all prior
arrangements between the parties regarding Dr. Sand's royalty rights under the
Original Assignment Agreement by hereby liquidating and terminating Dr. Sand's
rights to such royalties under the Original Assignment Agreement in exchange for
warrants of common stock in Sunrise Technologies International, Inc. to the
mutual benefit of the parties; and

NOW THEREFORE, in consideration of the foregoing and the mutual covenants
contained herein, the parties hereto agree that the Original Assignment
Agreement shall be and is hereby amended and restated in its entirety as
follows:

                                       1
<PAGE>   2

                                    ARTICLE 1

                                   DEFINITIONS

1.1     "Affiliates" means any corporations or other entities that control, are
        controlled by, or are under common control with a particular entity.
        "Control" means the ownership directly or indirectly of fifty percent
        (50%) or more of the shares entitled to vote for the election of
        directors (or other managing authority) of the subject entity, so long
        as that control exists.

1.2     "Combination Products" means products that comprise (i) a Product, and
        (ii) at least one other product or component that is sold together with
        the Product as a single unit.

1.3     "Products" means a laser device for the shrinking of collagen tissue,
        comprising: (i) a laser source (including power supply); and (ii) a
        device through which the laser beam is delivered to the collagen tissue;
        if Sunrise's manufacture or sale of such device would directly or
        contributorily infringe or induce infringement of a Valid Claim in the
        country for which the device is made or in which the device is sold.

1.4     "Patent Rights" means all worldwide rights of Dr. Sand to any subject
        matter described, claimed or covered by any of the patents or patent
        applications listed in Exhibit A, including any foreign counterparts,
        continuations, continuations-in-part, divisions, and reissues, and
        extensions of any of the foregoing.

1.5     "Related Technology" means all ideas, know-how, trade secrets, data,
        inventions, discoveries and any other proprietary rights (excluding the
        Patent Rights) related to the Patent Rights developed in whole or in
        part by Dr. Sand prior to or during the term of this Agreement.

1.6     "Valid Claim" means a claim of an issued and unexpired patent included
        within the Patent Rights that has not been held unenforceable,
        unpatentable or invalid by a decision of a court or governmental agency
        of competent jurisdiction, and that has not been admitted to be invalid
        or unenforceable through reissue, disclaimer or otherwise.

                                    ARTICLE 2

                                   ASSIGNMENT

2.1     Assignment. Dr. Sand hereby irrevocably assigns exclusively to Sunrise
        all worldwide rights in and to the Patent Rights and Related Technology,
        including, without limitation, all of the patents or patent applications
        listed in Exhibit A, and all foreign counterparts, continuations,
        continuations-in-part, divisions, and reissues and extensions of any of
        the foregoing and the exclusive right to exclude

                                       2
<PAGE>   3

        others from making, using and selling any products, and to practice any
        process, procedure or method covered by and otherwise exploit the Patent
        Rights and Related Technology and the exclusive right to maintain and
        defend actions with respect to all of the foregoing.

2.2     Delivery of Technical Information. Promptly after signing this Agreement
        and continuously during the term hereof, Dr. Sand shall convey to
        Sunrise all data, documentation and other physical embodiments of the
        Related Technology required by Sunrise for its complete understanding
        and effective use of the Related Technology.

                                    ARTICLE 3

                                     PAYMENT

3.1     Subject to the terms of the Royalty Acceleration Agreement, Sunrise and
        Dr. Sand hereby agree to terminate the payment of all royalties to Dr.
        Sand on sales of Products and Combination Products as provided for in
        the Original Assignment Agreement in exchange for a warrant (the
        "Warrant") to purchase 750,000 shares of common stock of Sunrise at an
        exercise price of $.01 per share, which shall be substantially in the
        form of Exhibit B attached hereto. Dr. Sand shall assign the patent
        titled "Prevention of Regression in Refractive Keratoplasty" application
        #09\550,579. On the date hereof, Sunrise shall no longer make royalty
        payments to Dr. Sand, and no royalties shall be paid to Dr. Sand under
        any agreement or arrangement with Sunrise.

3.2     Subject to the terms of the Royalty Acceleration Agreement, Dr. Sand
        hereby agrees (i) to accept the Warrant in exchange for the termination
        of all of his royalty rights on the sales of Products and Combination
        Products as provided for in the Original Assignment Agreement and (ii)
        to assign to Sunrise free of all liens and claims all the patents and
        technologies contemplated in the Amended and Restated Patent and
        Technology Assignment Agreement as more specifically described in
        Exhibit A hereto as well as assign the patent titled "Prevention of
        Regression in Refractive Keratoplasty" application #09\550,579.

                                   ARTICLE 4

                              TERM AND TERMINATION

4.1     Unless sooner terminated pursuant to this Article 4, this Agreement
        shall commence upon the Restatement Effective Date and shall
        automatically expire upon the later of (a) the expiration of the
        last-to-expire patent within the Patent Rights, or (b) the abandonment
        of the last application within the Patent Rights.

                                       3
<PAGE>   4

        All of the provisions of this Agreement shall survive expiration of this
        Agreement except Article 7, which shall terminate.

4.2     Termination for Breach. Either party shall have the right to terminate
        this Agreement by written notice if the other party materially breaches
        this Agreement and has failed to cure such breach within sixty (60) days
        of receipt of written notice from the nonbreaching party describing such
        default and its intention to terminate this Agreement.

4.3     General. Upon the expiration or termination of this Agreement for any
        reason, nothing herein shall be construed to release either party from
        any obligation that matured prior to the effective date of such
        termination.

                                    ARTICLE 5

                                 CONFIDENTIALITY

5.1     Obligations of Dr. Sand. All scientific and technical information known
        or possessed by Dr. Sand concerning the Patent Rights or the Related
        Technology shall be deemed "Confidential Information." Dr. Sand shall
        not disclose or provide any such Confidential Information to any third
        party without the other party's prior written consent.

5.2     Obligations of Sunrise. Sunrise shall protect the Confidential
        Information in a manner consistent with Sunrise's protection of its
        other confidential information.

                                    ARTICLE 6

                         REPRESENTATIONS AND WARRANTIES

6.1     By Dr. Sand. Dr. Sand represents and warrants to Sunrise that:

        (A)     Dr. Sand is the sole owner of the Patent Rights and, to the best
                of his knowledge, of the Related Technology, and has the full
                right and authority to enter into this Agreement and grant the
                licenses granted herein;

        (B)     Dr. Sand has not previously granted and will not grant during
                the term of this Agreement any rights in the Patent Rights or
                Related Technology (except for the grant included in the
                Original Assignment Agreement and the Restated Agreement, both
                of which are superseded by this Agreement and have no further
                force or effect);

        (C)     Dr. Sand is not aware of any claims that would invalidate any
                patent(s) or patent applications listed in Exhibit A;

                                       4
<PAGE>   5

        (D)     Exhibit A includes all patents and patent applications owned by
                Dr. Sand, or claiming inventions made in whole or in part by Dr.
                Sand, prior to the Effective Date. Dr. Sand owns no rights, and
                to the best of his knowledge, no other person or entity owns any
                rights in any patent or patent application the claims of which
                would dominate the claims of a patent or application within the
                Patent Rights or necessarily be infringed by Sunrise's
                manufacturing, sale or use of the Products; and

        (E)     This Agreement constitutes Dr. Sand's legal, valid and binding
                agreement. Dr. Sand's execution, delivery and performance of
                this Agreement will not constitute a violation or breach of any
                agreement or contract to which Dr. Sand is a party or by which
                Dr. Sand is bound, or the terms of any judicial or
                administrative decree to which Dr. Sand is subject.

6.2     By Sunrise. Sunrise represents and warrants to Dr. Sand that:

        (A)     Sunrise's Board of Directors has approved Sunrise's entering
                into and performing this Agreement; and

        (B)     This Agreement constitutes Sunrise's legal, valid and binding
                agreement. Sunrise's execution, delivery and performance of this
                Agreement will not constitute a violation or breach of any
                agreement or contract to which Sunrise is a party or by which
                Sunrise is bound, or the terms of any judicial or administrative
                decree to which the Sunrise is subject.

                                    ARTICLE 7

                               PROCESS DESIGNATION

        Sunrise and Dr. Sand agree to designate as "the Sand Process" the method
of shrinking collagen comprising the step of irradiating tissue with energy
having a wavelength in the range of about 1.80 to 2.55 microns to permit that
dissemination so as to create public association of the designation with the
method in and, wherever reasonably possible to promote that designation so as to
create public association of the designation with the method. In particular,
Sunrise agrees to identify the "Sand Process" in all Sunrise financial or
earnings public releases, all Sunrise press releases, all sales materials used
to solicit customers, including, but not limited to, videos, CD's, and websites,
and on all exhibit booths at trade shows.

                                    ARTICLE 8

                       PATENT PROSECUTION AND MAINTENANCE

        Sunrise shall have the right, at its expense and in its sole discretion
to maintain and apply for, seek prompt issuance of, and maintain any patents
within the Patent

                                       5
<PAGE>   6

Rights. Sunrise shall keep Dr. Sand reasonably informed of all material
developments in connection with the prosecution and maintenance of the Patent
Rights.

                                    ARTICLE 9

                                  INFRINGEMENT

9.1     Notification. Sunrise and Dr. Sand shall promptly inform the other in
        writing of any alleged infringement of which it shall have notice by a
        third party of any patents within the Patent Rights and provide the
        other party with any available evidence of infringement.

9.2     Enforcement. Sunrise shall have the exclusive right, but shall not be
        obligated, to prosecute at its own expense, any such infringements of
        the Patent Rights and/or Related Technology and, in furtherance of such
        right, Dr. Sand hereby agrees that during the term of this Agreement,
        Sunrise may join Dr. Sand as a party plaintiff in any such suit or
        proceeding, without expense to Dr. Sand. The total cost of any such
        infringement action commenced by Sunrise shall be borne by Sunrise.

9.3     Infringement of Others' Rights. If Sunrise receives a claim by a third
        party that practice of the Patent Rights or Related Technology by
        Sunrise infringes proprietary rights of any third party, Sunrise shall
        defend any action or proceeding against Dr. Sand and may, at its option,
        defend any action or proceeding against Sunrise with respect to such
        claim. Dr. Sand shall give Sunrise prompt notice of the commencement of
        any such action or proceeding or of any claim of infringement, shall
        furnish to Sunrise a copy of each communication relating to the alleged
        infringement and shall give Sunrise all authority, including the right
        to exclusive control of the defense and settlement of any such action or
        proceeding, and shall render all information and assistance necessary to
        such defense or settlement.

        Sunrise shall pay any expenses, including attorney's fees, incurred by
        either party in connection with any such action or proceeding, any
        damages and costs finally awarded against the infringing party and the
        amount of any settlement approved by Sunrise with respect to any such
        action or proceeding.

9.4     Cooperation. In any infringement suit Sunrise may institute to enforce
        or defend the Patent Rights and Related Technology pursuant to this
        Agreement, Dr. Sand shall, at the request of Sunrise, cooperate in all
        respects and, shall testify when requested and make available relevant
        records, papers and information.

                                       6
<PAGE>   7

                                   ARTICLE 10

                                   ASSIGNMENT

        Dr. Sand agrees that his rights and obligations under this Agreement may
not be assigned without the prior written consent of Sunrise. Dr. Sand may
assign his right to receive Warrants under this Agreement provided he gives
written notice of the assignment to Sunrise. Sunrise may assign or otherwise
transfer this Agreement and the rights granted hereunder (i) to any entity to
which Sunrise has assigned, sold, leased, transferred or otherwise disposed of
all or substantially all of the assets of Sunrise; or (ii) to any successor
corporation resulting from any merger or consolidation of Sunrise with or into
another corporation; or (iii) to one of its Affiliates, provided that any
permitted assignee or transferee shall agree in writing to comply with all the
terms and conditions applicable to Sunrise under this Agreement.

                                   ARTICLE 11

                                     NOTICE

11.1    Notices. Any notice, request, demand or other communication by the terms
        hereof required or permitted to be given by one party to another shall
        be given in writing by registered mail, postage prepaid, addressed to
        such other party or delivered to such other party as follows:

        Sunrise:   Sunrise Technologies International, Inc.
                   3400 West Warren Avenue
                   Fremont, California 94538
                   Attn:   John Hendrick
                           Senior VP, COO
                   Phone   510.771.2307
                   Fax     510.623.9163 (fax)
                   e-Mail  jhendrick@sunrise-tech.com

        with copy to: Duane, Morris & Heckscher LLP
                      227 W. Monroe Street
                      Suite 3400
                      Chicago, Illinois 60606
                      Attn:   Eric Fogel, Esq.
                      e-Mail  emfogel@duanemorris.com

        Dr. Sand:  Bruce J. Sand, M.D., F.A.C.S.
                   638 Lindero Canyon Road
                   Suite 507
                   Oak Park, California 91301
                   Phone   818.991.2374
                   Fax     818.991.2264

                                       7
<PAGE>   8

        with copy to: Edward Vincent King, Jr.
                      King & Kelleher LLP
                      One Embarcadero Center
                      17th Floor
                      San Francisco, California 94111
                      Phone   415.781.2888
                      Fax     415.781.3011
                      E-Mail  evking@kingandkelleher.com

or at such other address as may be given by any one of the parties. Any notice
required or permitted under this Agreement shall be in writing and shall be
deemed to be given upon the date of personal delivery or within three (3) days
of being mailed anywhere in the continental United States as registered mail
postage prepaid and addressed to the addressee at his last address recorded on
the records of Sunrise. Provided however, that during any postal interruption,
the said three (3) day period shall not be deemed to commence running until
after the termination of such postal interruption.

                                   ARTICLE 12

                            MISCELLANEOUS PROVISIONS

12.1    Governing Law. This Agreement shall be construed, governed, interpreted
        and applied in accordance with the laws of the State of California as if
        executed and fully performed within California, except that questions
        affecting the construction and effect of any patent shall be determined
        by the law of the country in which the patent was granted.

12.2    Jurisdiction, Venue. All disputes arising out of this Agreement shall be
        subject to binding arbitration in accordance with the Commercial
        Arbitration Rules of the American Arbitration Association. The exclusive
        venue of the arbitration shall be in Santa Clara County, California and
        the parties consent to the personal and exclusive jurisdiction and venue
        of such arbitration. A judgment may be entered upon any arbitration
        award by a court of competent jurisdiction.

12.3    Marketing. Sunrise intends to use commercially reasonable efforts to
        bring one or more Products to market and to meet the market demand
        therefor. However, nothing in this Agreement shall be deemed to require
        Sunrise to exploit the Patent Rights or the Related Technology nor
        prevent Sunrise from commercializing products similar to or competitive
        with Products, in addition to or in lieu of the Products.

12.4    Entire Agreement. The parties hereto acknowledge that this Amended and
        Restated Patent and Technology Agreement, along with the Consultant
        Agreement, the Non-Disclosure Agreement, and the Royalty Acceleration
        Agreement, all of which are dated the date hereof, set forth the entire
        agreement

                                       8
<PAGE>   9

        and understanding of the parties hereto as to the subject matter hereof,
        and shall not be subject to any change or modification except by the
        execution of a written instrument subscribed to by the parties hereto.
        Without limiting the foregoing, it is understood that the Original
        Assignment Agreement and all other agreements whether oral or written
        between the parties existing on the Restatement Effective Date are
        superseded by this Amended and Restated Patent and Technology Agreement
        and shall have no further force or effect whatsoever.

12.5    Severability. The provisions of this Agreement are severable, and in the
        event that any provisions of this Agreement are determined to be invalid
        or unenforceable under any controlling body of law, such invalidity or
        enforceability shall not in any way affect the validity or
        enforceability of the remaining provisions hereof.

12.6    No Waiver. The failure of either party to assert a right hereunder or to
        insist upon compliance with any term or condition of this Agreement
        shall not constitute a waiver of that right or excuse a subsequent
        failure to perform any such term or condition by the other party.

12.7    LIMITATION OF LIABILITY. EXCEPT FOR DAMAGES FROM BREACH OF ARTICLE 5,
        NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL,
        INDIRECT, CONSEQUENTIAL OR INCIDENTAL DAMAGES ARISING OUT OF THIS
        AGREEMENT.

12.8    Product Liability. Sunrise shall defend, indemnify and hold Dr. Sand
        harmless from and against all claims and expenses, including reasonable
        attorneys' fees, arising out of the death of or bodily injury to any
        person or persons or out of any damage to property resulting from
        Sunrise's production, manufacture, sale, use or lease of the Products;
        provided that (i) Dr. Sand provides to Sunrise prompt notice of any such
        claim or expense, (ii) Sunrise shall not be obligated to indemnify Dr.
        Sand for any claim or expense in connection with any settlement unless
        Sunrise consents in writing to such settlement, and (iii) Sunrise shall
        have the exclusive right to defend any such claim.

12.9    No Partnership or Agency. Nothing in this Agreement shall constitute or
        be deemed to constitute a partnership or agency between the parties
        hereto.

12.10   Release of Claims. Except as otherwise set forth in this Amended and
        Restated Patent and Technology Assignment Agreement, Dr. Sand hereby
        releases, acquits and forever discharges Sunrise, its officers,
        directors, agents, attorneys, servants, employees, shareholders,
        successors, assigns and affiliates, of and from any and all claims,
        liabilities, demands, causes of action, costs, expenses, attorney's
        fees, damages, indemnities and obligations of every kind and nature, in
        law, equity or otherwise, known and unknown, suspected and unsuspected,
        disclosed and undisclosed, arising out of or in any way related to the
        following: all negotiations, understandings, agreements, oral and
        written, relating to (i) the

                                       9
<PAGE>   10

        acquisition of Laser Biotech Inc., (ii) all royalty and payment
        agreements involving Dr. Sand, Laser Biotech Inc., and/or Sunrise, (iii)
        any and all claims of mismanagement or improper conduct that in any way
        relates to the foregoing or relates to or arises out of the claims set
        forth in the Arbitration Demand, the Consultant Agreement and the
        Original Assignment Agreement. Notwithstanding the foregoing, nothing in
        this Agreement shall constitute a waiver of Dr. Sand's rights arising
        under the indemnification provisions provided herein.

12.11   Section 1542 Waiver. Dr. Sand acknowledges that he has read and
        understands Section 1542 of the Civil Code of the State of California
        which reads as follows:

                A general release does not extend to claims which the creditor
                does not know or suspect to exist in his favor at the time of
                executing the release, which if known by him must have
                materially affected his settlement with the debtor.

Dr. Sand hereby expressly waives and relinquishes all rights and benefits under
that section and any law or legal principle of similar effect in any
jurisdiction with respect to the release granted herein.

        IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.

SUNRISE TECHNOLOGIES                             BRUCE J. SAND, M.D.
INTERNATIONAL, INC.,
F/K/A LASER BIOTECH, INC.

By: /s/ JOHN N. HENDRICK                         By: /s/ BRUCE J. SAND, M.D.
   ----------------------------                     ----------------------------
                                                    Bruce J. Sand, M.D.
Name: John N. Hendrick
     --------------------------

Title: C.O.O.
      -------------------------

                                       10
<PAGE>   11

                                    EXHIBIT A

                        LIST OF PATENTS AND TECHNOLOGIES

<TABLE>
<CAPTION>
                                Grant/
Patent No.      Country       Issue/Date      Title
----------      -------       ----------      -----
<S>               <C>        <C>              <C>
#4,979,709        USA           6/30/89       "Method for Collagen Shrinkage"
#5,137,530        USA           6/29/90          "           "         "
#5,304,169        USA           8/17/92       "Method and Apparatus for Collagen Shrinkage"
#5,374,265        USA            8/6/92          "           "         "
#5,484,432        USA           1/16/96          "           "         "
#5,591,157        USA            1/7/97          "           "         "
#5,618,284        USA            4/8/97          "           "         "
EPO #0480995 International     10/19/94          "           "         "
     (see attachments)
#60/145,069       USA        July 20, 1999    "Antifibrotic Therapy in Ocular Pathology"
#60/161,147       USA        Oct. 22, 1999    "Remedial Cross-linking to Restore Lamellar
                                               Stability Following Thermal Refractive Keratoplasty"
#60/152,773       USA        Sept. 3, 1999    "Photothermal Refractive Keratoplasty"
#60/147,123       USA        Aug. 4, 1999     "Inhibition of the Biological Response to Injury
                                               from Wavefront-Guided Corneal Modification"
#60/137,459       USA        June 4, 1999     "Molecular and Cellular Biology of Wound Repair
                                               Following Refractive Keratoplasty"
#60/153,589       USA        Sept. 13, 1999   "Thermal Refractive Keratoplasty"
#09/550,579       USA        April 17, 2000   "Prevention of Regression in Refractive Keratoplasty"
</TABLE>
<PAGE>   12
                                    EXHIBIT B

                                 FORM OF WARRANT<PAGE>   1
                                                                    EXHIBIT 10.3

                                  SAND WARRANT

NEITHER THIS WARRANT NOR THE SECURITIES TO BE ISSUED UPON EXERCISE HEREOF HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR
UNDER THE SECURITIES LAWS OF ANY STATE. THIS WARRANT AND THE SECURITIES TO BE
ISSUED UPON EXERCISE HEREOF ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT
AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN
FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED
TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS.

                    SUNRISE TECHNOLOGIES INTERNATIONAL, INC.

               WARRANT FOR THE PURCHASE OF SHARES OF COMMON STOCK

    No. 2000 W-S-1                                        750,000 Shares

        FOR VALUE RECEIVED, SUNRISE TECHNOLOGIES INTERNATIONAL, INC., a
    corporation duly organized and existing under the laws of the State of
    Delaware (the "Company," which term includes any successor), with its
    principal office at 3400 West Warren Avenue, Fremont, California 94538,
    hereby certifies that Dr. Bruce Sand, M.D. (the "Holder") is entitled,
    subject to the provisions of this Warrant, to purchase from the Company, at
    any time after the Warrant Shares, as defined herein, are registered with
    the Securities and Exchange Commission (the "SEC"), but before 5:00 p.m.
    (Eastern Standard Time) on June 16, 2005 (the "Expiration Date"), the number
    of fully paid and nonassessable shares of Common Stock of the Company set
    forth above, subject to adjustment as hereinafter provided.

        The Holder may purchase such number of shares of Common Stock at a
    purchase price per share (as appropriately adjusted pursuant to Section 6
    hereof) of $.01 (the "Exercise Price"). The term "Common Stock" shall mean
    the aforementioned Common Stock of the Company, together with any other
    equity securities that may be issued by the Company in addition thereto or
    in substitution therefor as provided herein.

        The number of shares of Common Stock to be received upon the exercise or
    exchange of this Warrant and the price to be paid for a share of Common
    Stock are subject to adjustment from time to time as hereinafter set forth.
    The shares of Common Stock deliverable upon such exercise or exchange, as
    adjusted from time to time, are hereinafter sometimes referred to as
    "Warrant Shares."

                                      -1-
<PAGE>   2

        Section 1. Exercise of and Payment for Warrant. Subject to Sections 3,
    9, 10 and 11 (and in no event later than the Expiration Date), this Warrant
    may be exercised, in whole or in part on any business day on or before the
    Expiration Date by presentation and surrender hereof to the secretary of the
    Company at its principal office at the address set forth in the initial
    paragraph hereof (or at such other address as the Company may hereafter
    notify the Holder in writing) with the Purchase Form attached hereto as
    Exhibit A duly executed and accompanied by proper payment of the Exercise
    Price in one or more of the following methods, at the election of the Board
    of the Company:

               (a) cash;

               (b) check; or

               (c) surrender of other shares of Common Stock of the Company
    which: (A) either have been owned by the Holder for more than six (6) months
    on the date of surrender or were not acquired, directly or indirectly, from
    the Company; and (B) have a Current Market Price on the date of surrender
    equal to the Exercise Price of the Warrant Shares as to which the Warrant is
    being exercised.

        If this Warrant should be exercised in part only, the Company shall,
    upon surrender of this Warrant, execute and deliver a new Warrant evidencing
    the rights of the Holder thereof to purchase the balance of the Warrant
    Shares purchasable hereunder. Upon receipt by the secretary of the Company
    of this Warrant and such Purchase Form, together with proper payment of the
    Exercise Price, at such office, the Holder shall be deemed to be the holder
    of record of the Warrant Shares, notwithstanding that the stock transfer
    books of the Company shall then be closed or that certificates representing
    such Warrant Shares shall not then be actually delivered to the Holder. The
    Company shall pay any and all documentary stamp or similar issue or transfer
    taxes payable in respect of the issue or delivery of the Warrant Shares.
    Notwithstanding the above, no Warrant Shares will be issued unless such
    issuance shall comply with all relevant provisions of law and the
    requirements of any stock exchange upon which the Common Stock may then be
    listed.

        Section 2. Reservation of Shares. The Company hereby agrees that at all
    times there shall be reserved for issuance and delivery upon exercise or
    exchange of this Warrant all shares of its Common Stock or other shares of
    capital stock of the Company from time to time issuable upon exercise or
    exchange of this Warrant. All such shares shall be duly authorized and, when
    issued upon the exercise or exchange of the Warrant in accordance with the
    terms hereof, shall be validly issued, fully paid and nonassessable, free
    and clear of all liens, security interests, charges and other encumbrances
    or restrictions on sale (other than as provided in the Company's certificate
    of incorporation and any restrictions on sale set forth herein or pursuant
    to applicable federal and state securities laws) and free and clear of all
    preemptive rights.

        Section 3. Fractional Interest. The Company will not issue a fractional
    share of Common Stock upon exercise or exchange of this Warrant. Instead,
    the Company will

                                      -2-
<PAGE>   3

    deliver its check for the current market value of the fractional share. The
    current market value of a fraction of a share is determined as follows:
    multiply the Current Market Price of a full share by the fraction of a share
    and round the result to the nearest cent.

        Section 4. Assignment or Loss of Warrant.

               (a) This Warrant may not be transferred in any manner otherwise
    than by will or by the laws of descent or distribution and may be exercised
    during the lifetime of Holder only by him. The terms of this Warrant shall
    be binding upon the executors, administrators, heirs, successors, and
    assigns of the Holder.

               (b) Upon receipt of evidence satisfactory to the Company of the
    loss, theft, destruction or mutilation of this Warrant, and (in the case of
    loss, theft or destruction) of indemnification satisfactory to the Company,
    and upon surrender and cancellation of this Warrant, if mutilated, the
    Company shall execute and deliver a new Warrant of like tenor and date.

        Section 5. Rights of the Holder. The Holder shall not, by virtue hereof,
    be entitled to any rights of a stockholder in the Company, either at law or
    equity, and the rights of the Holder are limited to those set forth in this
    Warrant. Nothing contained in this Warrant shall be construed as conferring
    upon the Holder hereof the right to vote or to consent or to receive notice
    as a stockholder of the Company on any matters or with respect to any rights
    whatsoever as a stockholder of the Company. No dividends or interest shall
    be payable or accrued in respect of this Warrant or the interest represented
    hereby or the Warrant Shares purchasable hereunder until, and only to the
    extent that, this Warrant shall have been exercised or exchanged in
    accordance with its terms.

        Section 6. Adjustment of Exercise Price and Number of Shares. The number
    and kind of securities purchasable upon the exercise or exchange of this
    Warrant and the Exercise Price shall be subject to adjustment from time to
    time upon the occurrence of certain events, as follows:

               (a) Adjustment for Change in Capital Stock. If at any time after
    the date hereof, the Company:

                        (1)   pays a dividend or makes a distribution on its
                              Common Stock in shares of its Common Stock;

                        (2)   subdivides its outstanding shares of Common Stock
                              into a greater number of shares;

                        (3)   combines its outstanding shares of Common Stock
                              into a smaller number of shares;

                        (4)   makes a distribution on its Common Stock in shares
                              of its capital stock other than Common Stock; or

                                      -3-
<PAGE>   4

                        (5)   issues by reclassification of its Common Stock any
                              shares of its capital stock;

    then the Exercise Price in effect immediately prior to such action shall be
    adjusted so that the Holder may receive, upon exercise or exchange of this
    Warrant and payment of the same aggregate consideration, the number of
    shares of capital stock of the Company which the Holder would have owned
    immediately following such action if the Holder had exercised or exchanged
    the Warrant immediately prior to such action.

               The adjustment shall become effective immediately after the
    record date in the case of a dividend or distribution and immediately after
    the effective date in the case of a subdivision, combination or
    reclassification.

               (b) Deferral of Issuance or Payment. In any case in which an
    event covered by this Section 6 shall require that an adjustment in the
    Exercise Price be made effective as of a record date, the Company may elect
    to defer until the occurrence of such event: (i) issuing to the Holder, if
    this Warrant is exercised after such record date, the shares of Common Stock
    and other capital stock of the Company, if any, issuable upon such exercise
    over and above the shares of Common Stock or other capital stock of the
    Company, if any, issuable upon such exercise on the basis of the Exercise
    Price in effect prior to such adjustment; and (ii) paying to the Holder by
    check any amount in lieu of the issuance of fractional shares pursuant to
    Section 3.

               (c) When No Adjustment Required. No adjustment need be made for a
    change in the par value or no par value of the Common Stock.

               (d) Current Market Price. The "Current Market Price" per share of
    Common Stock on any date is the average of the Quoted Prices of the Common
    Stock for the 30 consecutive trading days prior to the date in question. The
    "Quoted Price" of the Common Stock is the last reported sales price of the
    Common Stock as reported by NASDAQ, or the primary national securities
    exchange on which the Common Stock is then quoted; provided, however, that
    if quotes for the Common Stock are not reported by NASDAQ and the Common
    Stock is neither traded on the NASDAQ National Market, on a national
    securities exchange, on the NASDAQ Small Cap Market nor on the OTC
    Electronic Bulletin Board, the price referred to above shall be the price
    reflected in the over-the-counter market as reported by the National
    Quotation Bureau, Inc. or any organization performing a similar function.

               (e) No Adjustment Upon Exercise of Warrants. No adjustments shall
    be made under any Section herein in connection with the issuance of Warrant
    Shares upon exercise or exchange of the Warrants.

               (f) Common Stock Defined. Whenever reference is made in Section
    6(a) to the issue of shares of Common Stock, the term "Common Stock" shall
    include any equity securities of any class of the Company hereinafter
    authorized which shall not be

                                      -4-
<PAGE>   5

    limited to a fixed sum or percentage in respect of the right of the holders
    thereof to participate in dividends or distributions of assets upon the
    voluntary or involuntary liquidation, dissolution or winding up of the
    Company. Subject to the provisions of Section 8 hereof, however, shares
    issuable upon exercise or exchange hereof shall include only shares of the
    class designated as Common Stock of the Company as of the date hereof or
    shares of any class or classes resulting from any reclassification or
    reclassifications thereof or as a result of any corporate reorganization as
    provided for in Section 8 hereof.

        Section 7. Officers' Certificate. Whenever the Exercise Price shall be
    adjusted as required by the provisions of Section 6, the Company shall
    forthwith file in the custody of its secretary or an assistant secretary at
    its principal office an officers' certificate showing the adjusted Exercise
    Price determined as herein provided, setting forth in reasonable detail the
    facts requiring such adjustment and the manner of computing such adjustment.
    Each such officers' certificate shall be signed by the chairman, president
    or chief financial officer of the Company and by the secretary or any
    assistant secretary of the Company. Each such officers' certificate shall be
    made available at all reasonable times for inspection by the Holder or any
    holder of a Warrant executed and delivered pursuant to Section 4 hereof.

        Section 8. Reclassification, Reorganization, Consolidation or Merger. In
    the event of any reclassification, capital reorganization or other change of
    outstanding shares of Common Stock of the Company (other than a subdivision
    or combination of the outstanding Common Stock or other change contemplated
    by Section 6(a) hereof and other than a change in the par value of the
    Common Stock) or in the event of any consolidation or merger of the Company
    with or into another corporation (other than a merger in which merger the
    Company is the continuing corporation and that does not result in any
    reclassification, capital reorganization or other change of outstanding
    shares of Common Stock of the class issuable upon exercise or exchange of
    this Warrant) or in the event of any sale, lease, transfer or conveyance to
    another corporation of the property and assets of the Company as an entirety
    or substantially as an entirety, the Company shall use its best efforts to
    cause effective provisions to be made so that the Holder shall have the
    right thereafter, by exercising this Warrant, to purchase the kind and
    amount of shares of stock and other securities and property (including cash)
    receivable upon such reclassification, capital reorganization and other
    change, consolidation, merger, sale or conveyance by a holder of the number
    of shares of Common Stock that might have been received upon exercise or
    exchange of this Warrant immediately prior to such reclassification, capital
    reorganization, change, consolidation, merger, sale or conveyance. Any such
    provision shall include provisions for adjustments in respect of such shares
    of stock and other securities and property that shall be as nearly
    equivalent as may be practicable to the adjustments provided for in this
    Warrant. The foregoing provisions of this Section 8 shall similarly apply to
    successive reclassifications, capital reorganizations and changes of shares
    of Common Stock and to successive consolidations, mergers, sales or
    conveyances.

                                      -5-
<PAGE>   6

        Section 9. Transfer to Comply with the Securities Act of 1933:
    Registration Rights.

               (a) No sale, transfer, assignment, hypothecation or other
    disposition of this Warrant or of the Warrant Shares, in whole or in part,
    shall be made unless any such transfer, assignment or other disposition will
    comply with the rules and statutes administered by the Securities and
    Exchange Commission and: (i) a Registration Statement under the Act
    including such shares is currently in effect; or (ii) in the opinion of
    counsel, which counsel and which opinion shall be reasonably satisfactory to
    the Company, a current Registration Statement is not required for such
    disposition of the shares. Each stock certificate representing Warrant
    Shares issued upon exercise or exchange of this Warrant shall bear the
    following legend (unless, in the opinion of counsel, which counsel and which
    opinion shall be reasonably satisfactory to the Company, such legend is not
    required):

           "THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
           SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE
           SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO
           RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED
           OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE
           SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE
           ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM
           AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY
           PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY
           APPLICABLE STATE SECURITIES LAWS."

        Section 10. Holder's Representations. In the event the Shares
    purchasable pursuant to the exercise of this Warrant have not been
    registered under the Securities Act of 1933, as amended, at the time this
    Warrant is exercised, Holder shall, concurrently with the exercise of all or
    any portion of this Warrant, deliver to the Company his Investment
    Representation Statement attached hereto as Exhibit B.

        Section 11. Modification and Waiver. Neither this Warrant nor any term
    hereof may be changed, waived, discharged or terminated other than by an
    instrument in writing signed by the Company and by the holder hereof.

        Section 12. Notices. Any notice, request or other document required or
    permitted to be given or delivered to the holder hereof or the Company shall
    be delivered or shall be sent by certified mail, postage prepaid, to each
    such holder at its address as shown on the books of the Company or to the
    Company at the address indicated therefor in the first paragraph of this
    Warrant.

                                      -6-
<PAGE>   7

        Section 13. Descriptive Headings and Governing Law. The description
    headings of the several sections and paragraphs of this Warrant are inserted
    for convenience only and do not constitute a part of this Warrant. This
    Warrant shall be construed and enforced in accordance with, and the rights
    of the parties shall be governed by, the laws of the State of Delaware.

        Section 14. Registration of Warrant Shares. The Company shall attempt to
    duly register the Warrant Shares with the SEC within 90 days after the
    execution of this Warrant.

        IN WITNESS WHEREOF, the Company has duly caused this Warrant to be
    signed by its duly authorized officer and to be dated as of June 16, 2000.

                                        SUNRISE TECHNOLOGIES INTERNATIONAL, INC.

                                            By: /s/ JOHN N. HENDRICK
                                               --------------------------------
                                                 Name: John N. Hendrick
                                                      -------------------------
                                                 Title: C.O.O.
                                                       ------------------------

                                      -7-
<PAGE>   8

                                    EXHIBIT A

                          NOTICE OF EXERCISE OF WARRANT

    Date:
         --------------------------

    To: Sunrise Technologies International, Inc.
        Attn: Secretary
        3400 West Warren Avenue
        Fremont, California  94538

    This is my notice to exercise my Warrant:
<TABLE>
<CAPTION>

    ------------------------------------------------------------------------------------------------
    <S>                    <C>                  <C>   <C>                <C>  <C>
    Grant Date             Number of Shares           Exercise Price          Total     Cost     of
                                                                               Exercised Shares
    ------------------------------------------------------------------------------------------------
                                                 x                        =
    ------------------------------------------------------------------------------------------------
                                                 x                        =
    ------------------------------------------------------------------------------------------------
                                                 x                        =
    ------------------------------------------------------------------------------------------------
                                                 x                        =
    ------------------------------------------------------------------------------------------------
                                                 x                        =
    ------------------------------------------------------------------------------------------------
    *PLEASE ENCLOSE A CASHIER'S CHECK FOR THE TOTAL COST OF SHARES YOU WISH TO
    EXERCISE. YOUR REQUEST WILL NOT BE PROCESSED WITHOUT PAYMENT.
</TABLE>

    Please deliver shares to:
                             ----------------------------------------------

                             Acct. No. (if applicable)
                                                      ----------------------

                                      -8-
<PAGE>   9

    I understand the exercise of this Warrant and my ownership of the shares is
    subject to all the terms and provisions of the Warrant and its related
    agreements.

    Print Name as it appears on share certificate  Signature of Holder

    Address                                        Telephone Number

    City/State/Zip                                 Social Security Number

    Approved:  Sunrise Technologies International, Inc.

    By:                                          Title:
       ------------------------------                  -----------------------

                                      -9-
<PAGE>   10

                                    EXHIBIT B

                       INVESTMENT REPRESENTATION STATEMENT

    PURCHASER:
              --------------------------------------------------------

    COMPANY:   SUNRISE TECHNOLOGIES INTERNATIONAL, INC.

    SECURITY:  COMMON STOCK

    AMOUNT:                      SHARES
           ----------------------

         In connection with the purchase of the above-listed Securities, I, the
    Purchaser, represent to the Company the following:

               (a) I am aware of the Company's business affairs and financial
    condition, and have acquired sufficient information about the Company to
    reach an informed and knowledgeable decision to acquire the Securities. I am
    purchasing these Securities for my own account for investment purposes only
    and not with a view to, or for the resale in connection with, any
    "distribution" thereof for purposes of the Securities Act of 1933, as
    amended (the "Securities Act").

               (b) I understand that the Securities have not been registered
    under the Securities Act in reliance upon a specific exemption therefrom,
    which exemption depends upon, among other things, the bona fide nature of my
    investment intent as expressed herein. In this connection, I understand
    that, in the view of the Securities and Exchange Commission (the "SEC"), the
    statutory basis for such exemption may be unavailable if my representation
    was predicated solely upon a present intention to hold these Securities for
    any fixed period in the future, including but not limited to, the minimum
    capital gains period specified under tax statutes, for a deferred sale, or
    until an increase or decrease in the market price of the Securities, or for
    a period of one year, or any other fixed period in the future.

               (c) I further understand that the Securities must be held
    indefinitely unless subsequently registered under the Securities Act or
    unless an exemption from registration is otherwise available. Moreover, I
    understand that the Company is under no obligation to register the
    Securities. In addition, I understand that the certificate evidencing the
    Securities will be imprinted with a legend which prohibits the transfer of
    the Securities unless they are registered or such registration is not
    required in the opinion of counsel for the Company.

               (d) I am familiar with the provisions of Rule 144, promulgated
    under the Securities Act, which, in substance, permits limited public resale
    of "restricted

                                      -10-
<PAGE>   11

    securities" acquired, directly or indirectly, from the issuer thereof, in a
    non-public offering subject to the satisfaction of certain conditions. The
    Securities may be resold in certain limited circumstances subject to the
    provisions of Rule 144, which requires among other things: (1) the
    availability of certain public information about the Company; (2) the resale
    occurring not less than one year after the party has purchased, and made
    full payment for, within the meaning of Rule 144, the securities to be sold;
    and, in the case of an affiliate, or a non-affiliate who has held the
    securities less than two years; and (3) the sale being made through a broker
    in an unsolicited "broker's transaction" or in transactions directly with a
    market maker (as said term is defined under the Securities Exchange Act of
    1934) and the amount of securities being sold during any three month period
    not exceeding the specified limitations stated therein, if applicable.

               (e) I agree, in connection with a public offering of the
    Company's securities, (1) not to sell, make short sale of, loan, grant any
    options for the purchase of, or otherwise dispose of any shares of Common
    Stock of the Company held by me (other than those shares included in the
    registration) without the prior written consent of the Company or the
    underwriters managing such underwritten public offering of the Company's
    securities for one hundred eighty (180) days from the effective date of such
    registration, and (2) I further agree to execute any agreement reflecting
    (1) above as may be requested by the underwriters at the time of the public
    offering; provided however that the officers and directors of the Company
    who own the stock of the Company also agree to such restrictions.

               (f) I further understand that in the event all of the applicable
    requirements of Rule 144 are not satisfied, registration under the
    Securities Act, compliance with Regulation A, or some other registration
    exemption will be required; the Staff of the SEC has expressed its opinion
    that persons proposing to sell private placement securities other than in a
    registered offering and otherwise than pursuant to Rule 144 will have a
    substantial burden of proof in establishing that an exemption from
    registration is available for such offers or sales, and that such persons
    and their respective brokers who participate in such transactions do so at
    their own risk.

                                      (Signature of Purchaser)

                                      Date:
                                           ------------------------

                                      -11-
<PAGE>   12

                           DRAFTER'S INFORMATION SHEET
                           (for Document Number 14995)

    1.  Number of Warrant Shares:
                                 -----------------------------------
    2.  Name of Warrant Holder:
                               -------------------------------------

    3.  Expiration Date:
                        --------------------------------------------

    4.  Exercise Price:
                       ---------------------------------------------

    5.  Date of Warrant:
                        --------------------------------------------

                                      -12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]